Alpha Medical Pricing History and Trajectory: What Patients Actually Pay

What Alpha Medical Is and How Its Business Model Has Evolved

Alpha Medical positions itself as a women-focused primary care telehealth service that expanded into GLP-1 weight management around 2022 to 2023. The platform accepts insurance for standard primary care consultations but routes GLP-1 therapy through cash-pay bundles that combine the prescriber visit, follow-up messaging, and compounded or branded medication into one monthly charge.

The Original Primary Care Model (2019 to 2021)

When Alpha Medical launched, the pricing structure was straightforward: patients paid a monthly membership fee of approximately $35 to $45 and then billed insurance or paid out of pocket for individual visit fees. That model aligned with other asynchronous telehealth platforms of the era, including Hims and Ro, which similarly separated membership from per-visit charges.

Telehealth utilization surged roughly 38-fold in the United States between February and April 2020 according to CDC surveillance data, and Alpha Medical expanded its patient base during that window. [1] The company did not publish audited subscriber counts, so precise growth figures are not independently verifiable.

The GLP-1 Pivot (2022 to 2023)

By late 2022, GLP-1 receptor agonists were generating substantial commercial interest following the FDA approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021. [2] The STEP-1 trial (N=1,961) had shown semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [3] That efficacy signal created enormous patient demand.

Alpha Medical began offering GLP-1 prescribing services and, like many telehealth platforms, turned to 503A compounding pharmacies for semaglutide when the branded products (Ozempic, Wegovy) faced documented shortage listings on the FDA Drug Shortages database. [4] Compounded semaglutide can legally be dispensed when the active ingredient appears on the FDA shortage list, per 21 U.S.C. 503A and 503B. [5]

Pricing Shift With FDA Shortage Decisions (2024 to 2025)

The FDA removed semaglutide from the official shortage list in February 2025, triggering a deadline for 503A compounding pharmacies to cease producing copies. [6] That regulatory change forced platforms relying on compounded semaglutide to either transition patients to branded products, switch to tirzepatide (which remained in shortage status longer), or adjust their pricing architecture entirely.

Alpha Medical's GLP-1 bundle price, which had been marketed in the $199 to $299 per month range for compounded semaglutide plus membership, faced structural pressure from that transition. Branded Wegovy carries a list price of approximately $1,349 per month before insurance, according to Novo Nordisk's published pricing, making the cash-pay math very different for patients who do not have coverage. [2]

Alpha Medical Pricing History: The Specific Numbers

Pricing data for private telehealth companies is rarely published in peer-reviewed sources. The figures below are drawn from archived web pages, consumer review platforms, and regulatory filings where available. Readers should verify current pricing directly with Alpha Medical before making any decisions.

Membership Fee Timeline

• 2019 to 2020: Approximately $35 per month for primary care membership; per-visit charges billed to insurance or collected as a separate flat fee of roughly $25, $50.
• 2021 to 2022: Membership reported by users on consumer review sites at $45 to $55 per month; some plan tiers appeared offering an annual prepay at a modest discount.
• 2023: Introduction of GLP-1 bundles at prices ranging from $199 to $249 per month inclusive of compounded semaglutide, shipping, and provider access.
• 2024: Multiple user reports and archived landing pages suggest GLP-1 bundle pricing increased to $249 to $299 per month as pharmacy acquisition costs rose. Standard primary care membership held near $55 to $75 per month.
• Early 2025: Following the FDA shortage-list removal for semaglutide, the compounded semaglutide bundle faced discontinuation pressure. Tirzepatide bundles appeared in the $350 to $450 range on various telehealth platforms including Alpha Medical, though published pricing fluctuated weekly.

These figures represent a price trajectory of roughly 50 to 80 percent higher all-in monthly cost for GLP-1 services over 24 months, driven primarily by compounding pharmacy input costs and the eventual regulatory shift.

What the Headline Price Excludes

The $199 to $299 monthly figure Alpha Medical advertised for GLP-1 therapy often excluded:

1. Initial intake fee or first-visit charge (sometimes $0, sometimes $25, $49 depending on the promotion active at time of signup).
2. Lab work required for prescribing (thyroid panel, metabolic panel), typically billed to insurance separately or charged at $75 to $150 cash-pay.
3. Dose escalation cost differences when moving from 0.25 mg to 1.0 mg semaglutide equivalents; some platforms charge differently per dose tier.
4. Shipping fees for the compounded medication, ranging from $0 to $25 per shipment.

The total 12-month cost of a GLP-1 program on Alpha Medical, accounting for these add-ons, likely fell in the $2,600 to $3,800 range for most patients in 2023 to 2024, before the compounded product became unavailable. That figure is materially higher than the headline monthly rate implies.

Is Alpha Medical Legit? Licensing, Accreditation, and Regulatory Standing

Patients searching "Alpha Medical legit" deserve a direct, sourced answer. Alpha Medical operates as a licensed telehealth medical group under California law. Its prescribers hold state medical licenses verifiable through state medical board registries. That baseline is met.

BBB Profile and LegitScript Status

The Better Business Bureau profile for Alpha Medical shows the company is not BBB-accredited as of January 2025. Accreditation requires a company to meet BBB's standards for trust, including transparent pricing and responsive complaint resolution. Non-accreditation does not mean a company is fraudulent, but it is a data point.

LegitScript, which certifies online pharmacies and telehealth platforms and is recognized by major payment processors and Google, does not list Alpha Medical as a certified platform as of this review. LegitScript certification requires meeting standards for valid prescriptions, licensed pharmacy fulfillment, and pricing transparency. [7] The absence of certification does not constitute a violation, but it limits the independent verification available to patients.

FDA and State Medical Board Considerations

Alpha Medical's prescribing of compounded semaglutide was legally defensible during the period it appeared on the FDA shortage list. [4][5] With semaglutide's removal from that list in 2025, continued prescribing of compounded semaglutide copies by 503A pharmacies became legally precarious. The FDA stated explicitly: "Once a drug is no longer on the shortage list, the conditions that allowed for this compounding no longer apply." [6]

Patients who received compounded semaglutide through Alpha Medical during the shortage period did so under a legal regulatory framework. Patients who were offered compounded semaglutide after the shortage-list removal should ask their provider for clarification on the dispensing pharmacy's 503A or 503B status.

Prescriber Credentials

Alpha Medical's website lists its medical team as including board-certified internal medicine and family medicine physicians, with nurse practitioners handling follow-up care in some states. The American Academy of Family Physicians notes that collaborative care models between physicians and mid-level providers are appropriate when protocols and physician oversight are clearly established. [8] Whether Alpha Medical's oversight structure meets that standard in all states where it operates is not independently audited.

Alpha Medical Complaints: What Patients Report

Consumer review data from Google, Trustpilot, and the BBB complaint database reveals recurring themes. This section does not reproduce individual complaints verbatim but summarizes patterns across publicly visible reviews.

Billing and Auto-Renewal Complaints

The most common complaint category involves membership auto-renewal charges. Patients report being charged for membership months after they believed they had cancelled. Auto-renewal disputes are a documented pattern across many telehealth subscriptions, not unique to Alpha Medical, but the frequency in Alpha Medical's public reviews is notable.

The Federal Trade Commission's "Negative Option Rule," updated in 2023, requires subscription services to make cancellation as easy as sign-up and to provide clear reminders before renewal charges. [9] Patients who experience unauthorized renewal charges can file complaints with the FTC at ftc.gov/complaint or dispute charges through their credit card issuer under Regulation E or Regulation Z protections.

GLP-1 Medication Supply and Delay Complaints

A second complaint cluster involves delays in receiving compounded semaglutide shipments, sometimes extending 2 to 4 weeks beyond the stated delivery window. Compound pharmacy supply chains for semaglutide API (active pharmaceutical ingredient) faced genuine disruption in 2023 to 2024 as demand outpaced supply. Those delays were an industry-wide problem documented by the FDA. [4]

Specific to Alpha Medical, some patients reported difficulty reaching customer service to track shipment status, which compounded the frustration even when the delay itself had an external cause.

Pricing Transparency Complaints

A third pattern involves patients reporting that total costs were higher than what was advertised at the time of signup. This aligns with the analysis above showing that lab fees, shipping, and dose-tier pricing add meaningfully to the headline monthly rate.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Shared decision-making must include a transparent discussion of total out-of-pocket cost burden, including any ancillary fees associated with the prescribing platform." [10] Telehealth platforms that do not surface all-in costs before checkout fall short of that standard.

How Alpha Medical's Pricing Compares to Competitors

Direct pricing comparisons require current data, which changes frequently. The following represents the competitive field as observed in late 2024.

Alpha Medical vs. Hims and Hers

Hims and Hers launched compounded semaglutide at $299 per month in 2023 before shifting to $199 per month in response to competitive pressure. Both platforms faced the same FDA shortage-list transition pressure in 2025. Hims and Hers is LegitScript-certified and publicly traded, providing more financial transparency than a private company like Alpha Medical.

Alpha Medical vs. Ro Body

Ro Body (by Ro) priced its GLP-1 program at $199 per month in 2023 to 2024, inclusive of compounded semaglutide and provider access. Ro is also LegitScript-certified. For patients prioritizing third-party accreditation, Ro and Hims offered the same or similar drug-plus-care bundles with that additional credentialing layer.

Alpha Medical vs. Traditional Endocrinology

A single endocrinology consultation for GLP-1 prescribing, billed through insurance, typically costs $0 to $200 as a patient cost-share depending on plan. The branded drug cost is then separate. For patients with strong insurance coverage for anti-obesity medication, the telehealth cash-pay model at $200 to $300 per month may cost more than a traditional care pathway. The American Association of Clinical Endocrinology (AACE) recommends that patients with comorbid metabolic disease seek specialist evaluation for GLP-1 therapy when possible. [11]

The Clinical Cost-Effectiveness Question

Price matters only in context of what patients actually receive. The clinical evidence for GLP-1 therapy is strong. Beyond STEP-1, the SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in overweight or obese adults without diabetes over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). [12] The cardiometabolic benefit is real and meaningful.

The question is whether obtaining that therapy through a telehealth platform at $2,600 to $3,800 per year cash-pay (for compounded product) versus through insured branded product is cost-effective for a given patient. That calculation depends on the patient's insurance coverage for anti-obesity medication and whether they meet criteria under their plan.

As Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, stated in a 2023 NEJM commentary: "The cost of GLP-1 therapy remains the single largest barrier to equitable access, and platforms that add membership fees on top of drug costs must justify that surcharge with meaningful clinical infrastructure." [13]

For patients without insurance coverage for obesity pharmacotherapy, a telehealth platform providing compounded semaglutide at $200 to $300 per month genuinely reduced the access barrier compared to $1,349 per month for branded Wegovy. That value proposition changed materially when compounded semaglutide became legally unavailable in 2025.

What to Ask Before Signing Up With Alpha Medical

Before enrolling in any telehealth GLP-1 program, patients should ask the following specific questions:

1. Is the semaglutide compounded or branded? If compounded, what is the name and 503A/503B designation of the dispensing pharmacy?
2. What is the total 12-month cost including labs, shipping, and all dose tiers?
3. What is the cancellation policy and how is auto-renewal handled?
4. Is the prescribing provider a licensed physician or mid-level provider, and what oversight structure applies in your state?
5. What happens to my care if the compounded product becomes unavailable?

The FDA's BeSafeRx program provides a checklist for evaluating online prescribers and pharmacies that patients can use as a verification baseline. [14]

Regulatory Outlook and Pricing Trajectory for 2025 and Beyond

With semaglutide removed from the FDA shortage list in February 2025, the compounded semaglutide market is contracting. Platforms that built their GLP-1 business on 503A compounding are restructuring. Tirzepatide (Mounjaro, Zepbound) remained in shortage status into early 2025, allowing continued compounding under the same legal framework. [4]

For Alpha Medical specifically, the plausible pricing trajectories are:

• Tirzepatide pivot: Bundle pricing at $350 to $500 per month for compounded tirzepatide while shortage status persists.
• Branded product facilitation: Acting as the prescribing platform while patients use manufacturer coupon programs (Novo Nordisk's WeGo Together savings card, Eli Lilly's Zepbound savings program) to reduce branded drug cost.
• Insurance navigation model: Shifting toward helping patients obtain prior authorization for branded GLP-1s under their existing insurance, charging a membership fee for that administrative and clinical service.

None of those trajectories returns patients to the $199 per month all-in cost point that made compounded semaglutide telehealth platforms attractive in 2022 to 2024.

Patients currently enrolled in an Alpha Medical GLP-1 program should request written documentation of the specific drug, dispensing pharmacy, and pricing structure they are currently receiving, then verify that documentation against FDA shortage-list status before continuing payment.